Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.28
-0.33 (-1.34%)
At close: Apr 23, 2026, 4:00 PM EDT
24.36
+0.08 (0.33%)
Pre-market: Apr 24, 2026, 9:04 AM EDT
Ultragenyx Pharmaceutical Revenue
In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. Ultragenyx Pharmaceutical had revenue of $207.28M in the quarter ending December 31, 2025, with 25.89% growth.
Revenue (ttm)
$673.00M
Revenue Growth
+20.18%
P/S Ratio
3.54
Revenue / Employee
$490,883
Employees
1,371
Market Cap
2.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 673.00M | 113.00M | 20.18% |
| Dec 31, 2024 | 560.00M | 126.00M | 29.03% |
| Dec 31, 2023 | 434.00M | 70.67M | 19.45% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 510.17M |
| Zai Lab | 460.16M |
| Tarsus Pharmaceuticals | 451.36M |
| Day One Biopharmaceuticals | 158.18M |
| Immunome | 6.94M |
RARE News
- 20 days ago - DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026 - PRNewsWire
- 25 days ago - Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - GlobeNewsWire
- 4 weeks ago - Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewsWire
- 4 weeks ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Benzinga
- 6 weeks ago - Ultragenyx's gene therapy helps control ammonia levels in late-stage study - Reuters
- 2 months ago - Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights - Newsfile Corp
- 2 months ago - Ultragenyx to Participate at Investor Conferences in March - GlobeNewsWire